title: Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
abstract: Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.
authors: Stephen M
authors: SM
authors: Stahl
mesh_terms: D006801:Humans; D010300:Parkinson Disease / Q000523:psychology*; D010880:Piperidines / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists / Q000627:therapeutic use*; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D058826:Serotonin 5-HT2 Receptor Agonists; D014508:Urea; C510793:pimavanserin